How to buy Dimerix shares
Own Dimerix shares in just a few minutes.
Dimerix Limited is a biotechnology business based in Australia. Dimerix shares (DXB) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Dimerix has a trailing 12-month revenue of around $2.3 million.
How to buy shares in Dimerix
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Dimerix . Find the share by name or ticker symbol: DXB. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Dimerix reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Dimerix . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Dimerix share priceUse our graph to track the performance of DXB stocks over time.
Dimerix shares at a glance
|52-week range||AUDA$0.095 - AUDA$0.78|
|50-day moving average||AUDA$0.5325|
|200-day moving average||AUDA$0.3381|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.018|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Dimerix stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$2.3 million|
|Gross profit TTM||$2.3 million|
|Return on assets TTM||-37.33%|
|Return on equity TTM||-75.14%|
|Market capitalisation||$48.4 million|
TTM: trailing 12 months
Dimerix share dividends
We're not expecting Dimerix to pay a dividend over the next 12 months.
Have Dimerix 's shares ever split?
Dimerix 's shares were split on a 1:20 basis on 22 October 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dimerix shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Dimerix shares which in turn could have impacted Dimerix 's share price.
Dimerix share price volatility
Over the last 12 months, Dimerix 's shares have ranged in value from as little as $0.095 up to $0.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Dimerix 's is 1.8018. This would suggest that Dimerix 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.
Frequently asked questions
Ask an Expert